Tarsus Pharmaceuticals, Inc. TARS Non-cash lease expense
Non-cash lease expense at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept tars:OperatingLeaseNoncashExpense.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s non-cash lease expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s non-cash lease expense?
- Tarsus Pharmaceuticals, Inc. (TARS) reported non-cash lease expense of $77K in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s non-cash lease expense changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s non-cash lease expense decreased by 53.0% year-over-year, from $164K to $77K.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s non-cash lease expense?
- Over 3 years (2022 to 2025), Tarsus Pharmaceuticals, Inc.'s non-cash lease expense has grown at a 13.7% compound annual growth rate (CAGR), from $464K to $682K.
- What does non-cash lease expense mean?
- This represents the portion of operating lease costs recognized as an expense that does not involve an immediate cash outflow. It reflects the systematic allocation of the right-of-use asset cost over the lease term. Monitoring this helps analysts distinguish between actual cash burn and accounting-based lease recognition.